Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (OlmetecŽ), launched in 2002 by Sankyo and now available in more than 20 countries around the world; the antiplatelet agent prasugrel (EfientŽ), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (LixianaŽ), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE). Daiichi Sankyo is based in Tokyo and today has 50 billion yen in capital. Source
No articles found.
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
We are ProQR, a company on a mission to create new medicines for patients in need....
We are ProQR, a company on a mission to create ...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.